1. Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy.
- Author
-
Guo H, Wang H, Gao M, Deng H, Zhang Y, Gong J, and Zhang W
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Mice, Nude, Drug Liberation, Mice, Inbred BALB C, Drug Delivery Systems, Drug Carriers chemistry, Hyaluronic Acid chemistry, Hyaluronan Receptors metabolism, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung metabolism, Cisplatin pharmacology, Cisplatin administration & dosage, Cisplatin chemistry, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms metabolism, Gefitinib pharmacology, Gefitinib chemistry, Gefitinib administration & dosage, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents administration & dosage, Nanogels chemistry
- Abstract
The combination of the standard platinum-based chemotherapy with EGFR-tyrosine kinase inhibitor Gefitinib (Gef) principally boosts the anticancer efficacy of advanced non-small cell lung cancer (NSCLC) through non-overlapping mechanisms of action, however the clinical trials of cisplatin (Cis) and Gef combination failed to show a therapeutic improvement likely due to compromised cellular influx of Cis with the Gef interference. To overcome the antagonism between Cis and Gef in anti-NSCLC therapy, here we demonstrated a self-targeted hyaluronan (HA) nanogel to facilitate the anticancer co-delivery by utilizing the HA's intrinsic targeting towards CD44, a receptor frequently overexpressed on lung cancer cells. The co-assembly between HA, Cis and Gef generated a HA/Cis/Gef nanogel of 177.8 nm, featuring a prolonged drug release. Unlike the Gef inhibited the Cis uptake, the HA/Cis/Gef nanogel efficiently facilitated the drug internalization through CD44-targeted delivery as verified by HA competition and CD44 knocking down in H1975 NSCLC model both in vitro and in vivo. Moreover, the HA/Cis/Gef nanogel significantly improved the anticancer efficacy and meanwhile diminished the side effects in reference to the combination of free Cis and Gef. This CD44-targeted HA/Cis/Gef nanogel provided a potent strategy to advance the platinum-based combination therapy towards optimized NSCLC therapy., Competing Interests: Declaration of competing interest The authors declare no conflict of interest., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF